← Leaderboards
David Fiorentino
Stanford University
$49,952
Attributed
$49,952
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $27.1K · FY2006–07$50K$37.5K$25K$12.5K$0
'06
'07
Funding mix
By agency
NIH$49,952 · 3
By mechanism
M01$49,952 · 3
Top collaborators
No co-investigators on record.
Most similar at Stanford University
Same institution · by research overlap
- Utkan Demirci$14,678,583
- Michael L Cleary$25,231,473
- Christy Irene Sandborg$3,382,068
- Tilman Schulte$7,488,309
- Peter R Parham$35,417,272
Others in their field
Top investigators on “United States National Institutes Of Health”
- Leonard Freedman · Leidos Biomedical Research, Inc.$816,847,401
- Sonia M Thomas · Research Triangle Institute$701,865,642
- David Heimbrook · Leidos Biomedical Research, Inc.$642,073,624
- Bambra Strokes · Ppd Development Lp$526,656,217
- Lawrence Corey · Fred Hutchinson Cancer Center$513,687,120
- Tracy L Nolen · Research Triangle Institute$474,487,152
Research focus
United States National Institutes Of HealthResearch PersonnelPlaySourceB-LymphocytesResourcesInstitutionPharmacodynamicsSafetySkinDrug KineticsDoseAutoimmune DiseasesCellsFundingGrantComputer Retrieval Of Information On Scientific Projects DatabaseLabelCd8b1 GeneCd4 Positive T LymphocytesCd20 AntigensAppearanceAffectDesign
Grant awards (3)
MULTIPLE DOSES OF TRX1 (ANTI-CD4 MAB) WHEN ADMINISTERED BY INTRAVENOUS INFUSION$14,628
M01 · FY2007 · RR · contact PI
RITUXIMAB IN THE TREATMENT OF PATIENTS WITH DERMATOMYOSITIS$8,193
M01 · FY2007 · RR · contact PI
RITUXIMAB IN THE TREATMENT OF PATIENTS WITH DERMATOMYOSITIS$27,131
M01 · FY2006 · RR · contact PI